Myasthenia Gravis Disease Treatment Market

The Myasthenia Gravis Disease Treatment Market comprises therapies for a chronic autoimmune disorder that causes debilitating skeletal muscle weakness. The primary customers are healthcare providers, including hospitals and specialized clinics, which procure and administer treatments. Key market growth is propelled by the rising prevalence of autoimmune disorders, significant advancements in diagnostic tools, and the development of targeted therapies like biologics and monoclonal antibodies.